Chemotherapy
Chemotherapy is a type of cancer treatment that uses anti-cancer drugs to target and destroy cancer cells, and may be administered with curative intent, for life prolongation, or symptom reduction; however, it can also affect normal, healthy cells, leading to side effects such as fatigue, hair loss, nausea, and infections. This treatment falls under the medical oncology discipline and can result in both temporary and long-term adverse effects, including issues like anemia, infertility, and memory and concentration problems.
Health Outcomes
- Accelerated Recovery of Chemotherapy-Induced Myelosuppression
- Adverse Effects Frequency
- Adverse Events
- Association with Serious Adverse Events
- Cancer Treatment Support
- Changed Hematology Parameter
- Delayed Onset of Grade 3 Dermatitis
- Delayed Oral Mucositis Onset
- Improved Breast Cancer Therapy Response
- Improved Neuropathy
- Improved Oral Mucositis
- Improved Oral Mucositis Healing
- Improved Recovery in Immunocompromised Individuals
- Improved Safety Profile
- Improved Taste Function
- Improved Tolerability
- Improved Vaccine Efficacy
- Increased Adverse Effect
- Increased Adverse Effects
- Increased Adverse Event
- Increased Adverse Event Incidence
- Increased Adverse Events
- Increased Adverse Reactions
- Increased Candida albicans Eradication
- Increased Cytotoxicity and Mucosal Damage Risk
- Increased Dose Tolerance
- Increased Emesis
- Increased GCSF Level
- Increased Infection Frequency
- Increased Nausea
- Increased Occurrence of Serious Adverse Events
- Increased Regrowing Hair Count
- Increased Sepsis
- Increased Weight Loss
- Maintained Cell Viability
- Mitigated Chemotherapy-Induced Mucositis
- No Mutagenicity
- Occurrence of Adverse Events
- Prevented Chemotherapy-Induced Peripheral Neuropathy
- Probiotic-Related Infection
- Protection Against Oral Candidiasis
- Reduced Adverse Event Frequency
- Reduced Antiemetic Medication Use
- Reduced Antilisterial Activity
- Reduced Breast Fullness
- Reduced Candida Albicans Survival
- Reduced Chemoradiotherapy-Related Adverse Event
- Reduced Chemotherapy-Induced Diarrhea
- Reduced Chemotherapy-Induced Peripheral Neuropathy
- Reduced Dysgeusia
- Reduced Gastrointestinal Adverse Events
- Reduced Hand Foot Syndrome Severity
- Reduced Hematocrit
- Reduced Immune Cell Activity
- Reduced Immune Protection
- Reduced Immunosuppression
- Reduced Immunosuppression-Related Spleen Injury
- Reduced Incidence of Oral Mucositis
- Reduced Intestinal Mucositis Severity
- Reduced Listeria Monocytogenes Survival
- Reduced Monocyte Count
- Reduced Mucositis
- Reduced Nausea
- Reduced Nausea Incidence
- Reduced Nausea Severity
- Reduced Nausea Symptom Severity
- Reduced Nausea and Vomiting
- Reduced Nausea and Vomiting Score
- Reduced Nausea and Vomiting Severity
- Reduced Neuropathy Total Symptom Score
- Reduced Oral Candida Colonization
- Reduced Oral Mucositis Incidence
- Reduced Oral Mucositis Severity
- Reduced Oral Mucositis Symptoms
- Reduced Packed Cell Transfusion
- Reduced Peripheral Neuropathy Grade
- Reduced Prospective Consumption
- Reduced Severe Oral Mucositis Duration
- Reduced Thrombocytopenia
- Reduced Vomiting
- Reduced Vomiting Duration
- Reduced Vomiting Symptoms
- Reduced White Blood Cell Count
- Reduced Xerostomia
- Regressed Esophagitis
- Safety And Tolerability
- Safety in Terms of Adverse Events
- Supportive Effect in Breast Cancer Management